Provided by Tiger Trade Technology Pte. Ltd.

Travere Therapeutics, Inc.

52.04
-1.4000-2.62%
Pre-market: 52.990.9500+1.83%07:57 EDT
Volume:1.65M
Turnover:85.89M
Market Cap:4.91B
PE:-109.22
High:53.44
Open:53.44
Low:51.45
Close:53.44
52wk High:68.73
52wk Low:22.59
Shares:94.26M
Float Shares:92.77M
Volume Ratio:0.62
T/O Rate:1.78%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4764
EPS(LYR):-0.2864
ROE:-236.35%
ROA:-3.73%
PB:200.04
PE(LYR):-181.73

Loading ...

BUZZ-Travere Therapeutics climbs after upsized $475 mln convertible financing

Reuters
·
May 07

BRIEF-Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering To Refinance 2029 Convertible Notes

Reuters
·
May 07

Travere prices upsized USD 475 million convertible senior notes due 2032

Reuters
·
May 07

Travere Therapeutics director Roy D. Baynes sells 4,500 shares for $209,925

Reuters
·
May 07

Travere CMO Jula Inrig disposes 22,485 shares for $1.01 million

Reuters
·
May 07

Travere Therapeutics CLO Elizabeth Reed disposes of shares worth $1.1 million

Reuters
·
May 07

Travere CFO Christopher R. Cline disposes 2,491 shares worth $115,287.45

Reuters
·
May 07

Travere Therapeutics director Jeffrey A. Meckler disposes 8,000 shares for $360,000

Reuters
·
May 07

Wells Fargo Remains a Buy on Travere Therapeutics (TVTX)

TIPRANKS
·
May 06

Travere Therapeutics announces $400M convertible senior notes offering

TIPRANKS
·
May 06

Travere Therapeutics plans USD 400 million convertible senior notes offering due 2032

Reuters
·
May 06

Travere Therapeutics Inc - to Offer $400 Mln Convertible Senior Notes Due 2032

THOMSON REUTERS
·
May 06

Travere Announces Proposed Convertible Senior Notes Offering to Refinance 2029 Convertible Notes

THOMSON REUTERS
·
May 06

Evercore ISI Keeps Their Buy Rating on Travere Therapeutics (TVTX)

TIPRANKS
·
May 05

Stock Track | Travere Therapeutics Soars 5.99% Intraday on Multiple Analyst Price Target Raises

Stock Track
·
May 05

Travere Therapeutics Inc : Jefferies Raises Target Price to $54 From $50

THOMSON REUTERS
·
May 05

Piper Sandler Reaffirms Their Buy Rating on Travere Therapeutics (TVTX)

TIPRANKS
·
May 05

Travere Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $57 From $47

THOMSON REUTERS
·
May 05

Travere Therapeutics Inc : Leerink Partners Raises Target Price to $55 From $50

THOMSON REUTERS
·
May 05

Travere Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 05